Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study

References

• Wauters M, Elseviers M, Vaes B, et al. Polypharmacy in a Belgian cohort of community-dwelling oldest old (80+). Acta Clin Belg. 2016;71(3):158–166.10.1080/17843286.2016.1148298
   PubMed Web of Science ®Google Scholar
• Qato DM, Wilder J, Schumm LP, et al. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176(4):473–482.10.1001/jamainternmed.2015.8581
   PubMed Web of Science ®Google Scholar
• Roebuck MC, Liberman JN, Gemmill-Toyama M, et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91–99.10.1377/hlthaff.2009.1087
   PubMed Web of Science ®Google Scholar
• Jha AK, Aubert RE, Yao J, et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). 2012;31(8):1836–1846.10.1377/hlthaff.2011.1198
   PubMed Web of Science ®Google Scholar
• Albayrak I, Aydogmus M, Ozerbil OM, et al. The association between bone mineral density, quality of life, quality of sleep and fatigue. Acta Clin Belg. 2016;71(2):92–98.10.1179/2295333715Y.0000000061
   PubMed Web of Science ®Google Scholar
• Lin JT, Lane JM. Rehabilitation of the older adult with an osteoporosis-related fracture. Clin Geriatr Med. 2006;22(2):435–447, x.10.1016/j.cger.2005.12.010
   PubMed Web of Science ®Google Scholar
• Grootaert V, De Keulenaer J, Boonen S, et al. Selecting an appropriate and reimbursed anti-osteoporotic treatment option: a practical tool in the Belgian setting. Acta Clin Belg. 2012;67(1):13–18.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031.10.1007/s00198-006-0322-8
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yun H, Matthews R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population. Arthritis Care Res (Hoboken). 2012;64(7):1054–1060.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Adachi JD, Rampakakis E, et al. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res. 2012;27(1):202–210.10.1002/jbmr.533
   PubMed Web of Science ®Google Scholar
• Available from: http://www.shef.ac.uk/FRAX/
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.10.1016/0022-3956(75)90026-6
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group* under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34(7):939–944.10.1212/WNL.34.7.939
   PubMed Web of Science ®Google Scholar
• Gold G, Giannakopoulos P, Montes-Paixao C, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology. 1997;49(3):690–694.10.1212/WNL.49.3.690
   PubMed Web of Science ®Google Scholar
• Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1982;17(1):37–49.10.1016/0022-3956(82)90033-4
   PubMed Web of Science ®Google Scholar
• Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–186.10.1093/geront/9.3_Part_1.179
   PubMed Web of Science ®Google Scholar
• Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–320.10.2217/1745509X.4.3.311
   Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822.10.1056/NEJMoa067312
   PubMed Web of Science ®Google Scholar
• Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150(4):841–845.10.1001/archinte.1990.00390160093019
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–1847.10.1001/archinte.166.17.1842
   PubMedGoogle Scholar
• Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff (Millwood). 2003;22(4):220–229.10.1377/hlthaff.22.4.220
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–287.10.1016/j.maturitas.2004.02.005
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int. 2007;18(6):711–719.10.1007/s00198-006-0294-8
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414–2419.10.1001/archinte.165.20.2414
   PubMed Web of Science ®Google Scholar
• Devold HM, Furu K, Skurtveit S, et al. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297–304.10.1002/pds.2344
   PubMed Web of Science ®Google Scholar
• Feldstein AC, Nichols GA, Elmer PJ, et al. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am. 2003;85-A(12):2294–2302.10.2106/00004623-200312000-00005
   PubMedGoogle Scholar
• Warriner AH, Curtis JR. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol. 2009;21(4):356–362.10.1097/BOR.0b013e32832c6aa4
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435–1441.10.1359/jbmr.080418
   PubMed Web of Science ®Google Scholar
• Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251–3259.10.1210/jc.2009-2778
   PubMed Web of Science ®Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209–216.
   PubMed Web of Science ®Google Scholar
• Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs. 2004;30(7):33–43.10.3928/0098-9134-20040701-08
   PubMedGoogle Scholar
• Rieckmann N, Kronish IM, Haas D, et al. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J. 2006;152(5):922–927.10.1016/j.ahj.2006.05.014
   PubMed Web of Science ®Google Scholar
• Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266–1271.10.1016/j.amjcard.2011.12.017
   PubMed Web of Science ®Google Scholar
• Pfistermeister B, Tümena T, Gaßmann KG, et al. Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. PLOS ONE. 2017;12(2):e0171353.10.1371/journal.pone.0171353
   PubMed Web of Science ®Google Scholar
• Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian prescription database. Acta Obstet Gynecol Scand. 2013;92(10):1208–1215.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47(3):334–341.10.1097/MLR.0b013e31818afa1c
   PubMed Web of Science ®Google Scholar
• Hansen KE, Swenson ED, Baltz B, et al. Adherence to alendronate in male veterans. Osteoporos Int. 2008;19(3):349–356.10.1007/s00198-007-0471-4
   PubMed Web of Science ®Google Scholar
• Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117–1123.10.1210/jc.2003-030501
   PubMed Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896–905.10.1111/ijcp.2006.60.issue-8
   PubMed Web of Science ®Google Scholar